Diamond Therapeutics has now dosed the first cohort of its Phase I low-dose psilocybin clinical trial.
A study undertaken over a five-year period has shown that a single dose of ketamine improved thinking and reasoning in people who had expressed thoughts of...
A small study has reported that two doses of psilocybin received with supportive psychotherapy relieves depression.
For the multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD (MAPPUSX) sponsored by MAPS, Numinus will manage two new clinics in Montreal and Vancouver.
The largest psilocybin therapy clinical trial ever conducted, investigating psilocybin for treatment-resistant depression (TRD), has achieved its primary endpoint.
Kicking off the Microdose Wonderland conference in Miami, Cybin Inc announced it will be moving its psilocybin analogue – CYB003 – into clinical trials.
The findings from a Phase II A/B study, which is the world’s first study on ketamine-assisted psychotherapy for alcohol use disorder, will be published in the...
Braxia Scientific Corp.
Biotechnology company Beckley Psytech has welcomed neuroscience expert Dr Frank Wiegand to its team as Chief Medical Officer.
Researchers have discovered changes in the brain associated with LSD which they say could help gain insights into how the brain generates behaviour.
